Logowanie
Zarejestruj się
Zresetuj hasło
Publikuj i Dystrybuuj
Rozwiązania Wydawnicze
Rozwiązania Dystrybucyjne
Dziedziny
Architektura i projektowanie
Bibliotekoznawstwo i bibliologia
Biznes i ekonomia
Chemia
Chemia przemysłowa
Filozofia
Fizyka
Historia
Informatyka
Inżynieria
Inżynieria materiałowa
Językoznawstwo i semiotyka
Kulturoznawstwo
Literatura
Matematyka
Medycyna
Muzyka
Nauki farmaceutyczne
Nauki klasyczne i starożytne studia bliskowschodnie
Nauki o Ziemi
Nauki o organizmach żywych
Nauki społeczne
Prawo
Sport i rekreacja
Studia judaistyczne
Sztuka
Teologia i religia
Zagadnienia ogólne
Publikacje
Czasopisma
Książki
Materiały konferencyjne
Wydawcy
Blog
Kontakt
Wyszukiwanie
EUR
USD
GBP
Polski
English
Deutsch
Polski
Español
Français
Italiano
Koszyk
Home
Czasopisma
Slovenian Journal of Public Health
Tom 60 (2021): Zeszyt 4 (December 2021)
Otwarty dostęp
Relationship between quality of life indicators and cardiac status indicators in chemotherapy patients
Blaž Matija Geršak
Blaž Matija Geršak
,
Andreja Kukec
Andreja Kukec
,
Henning Steen
Henning Steen
,
Moritz Montenbruck
Moritz Montenbruck
,
Maja Šoštarič
Maja Šoštarič
,
Arne Kristian Schwarz
Arne Kristian Schwarz
,
Sebastian Esch
Sebastian Esch
,
Sebastian Kelle
Sebastian Kelle
,
Sorin Giusca
Sorin Giusca
,
Grigorios Korosoglou
Grigorios Korosoglou
,
Pia Wülfing
Pia Wülfing
,
Susan Dent
Susan Dent
oraz
Daniel Lenihan
Daniel Lenihan
| 20 paź 2021
Slovenian Journal of Public Health
Tom 60 (2021): Zeszyt 4 (December 2021)
O artykule
Poprzedni artykuł
Następny artykuł
Abstrakt
Artykuł
Ilustracje i tabele
Referencje
Autorzy
Artykuły w tym zeszycie
Podgląd
PDF
Zacytuj
Udostępnij
Article Category:
Original scientific article
Data publikacji:
20 paź 2021
Zakres stron:
199 - 209
Otrzymano:
09 mar 2021
Przyjęty:
31 mar 2021
DOI:
https://doi.org/10.2478/sjph-2021-0028
Słowa kluczowe
antineoplastic agents
,
cardiotoxicity
,
ventricular function – left
,
ventricular function – right
,
quality of life
,
magnetic resonance imaging
,
cine
,
echocardiography
,
lymphoma
,
Hodgkin disease
,
breast neoplasms
© 2021 National Institute of Public Health, Slovenia, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
EQ-5D questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 2
EQ-5D questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 3
EQ-5D questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 4
SF-36 physical component questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 5
SF-36 physical component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 6
SF-36 physical component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 7
SF-36 mental component questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 8
SF-36 mental component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 9
SF-36 mental component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Podgląd